Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL E JONES

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1083611636
CMS profile
94620
Location
CRESTVIEW HILLS, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$217.85

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $196.73 8
Consulting Fee $21.12 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL E JONES

NPI 1083611636 · CMS profile ID 94620

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CRESTVIEW HILLS, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083611636?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL E JONES, NPI 1083611636, CMS profile ID 94620. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083611636?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MICHAEL E JONES, NPI 1083611636, CMS profile ID 94620. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083611636?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MICHAEL E JONES, NPI 1083611636, CMS profile ID 94620, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1083611636?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $217.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $17.4812/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673646897 CMS
AbbVie, Inc. $15.6710/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647968083 CMS
AbbVie, Inc. $21.0810/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647968109 CMS
Daiichi Sankyo Inc. $15.7208/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695350415 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.6407/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684767707 CMS
Janssen Scientific Affairs, LLC $79.0006/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657596787 CMS
Gilead Sciences, Inc. $14.6705/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681537597 CMS
Intercept Pharmaceuticals, Inc. $21.1202/06/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702085757 CMS
AbbVie, Inc. $12.4701/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647967899 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $217.85 9
PY2020 $129.84 7
PY2021 $337.52 11
PY2022 $257.93 9
PY2023 $258.68 17
PY2024 $310.01 9
PY2025 $392.84 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $304,950.60 133
PY2024 Principal investigator $457,323.22 237
PY2023 Principal investigator $533,333.42 238
PY2022 Principal investigator $150,301.11 166
PY2021 Principal investigator $55,731.60 19
PY2020 Principal investigator $143,151.70 114
PY2019 Principal investigator $258,588.69 68

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

166 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,167.60 12/23/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885260173
Principal investigator 1 Janssen Research & Development, LLC $6,245.00 12/19/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885260175
Principal investigator 1 ABBVIE INC. $1,214.00 12/15/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890370101
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 12/08/2022 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 885224573
Principal investigator 1 Janssen Research & Development, LLC $7,440.00 12/08/2022 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 885224575
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.00 12/08/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937179333
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.00 12/08/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937179335
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $225.30 12/08/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937179337
Principal investigator 1 Janssen Research & Development, LLC $1,950.40 12/01/2022 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 885224569
Principal investigator 1 Janssen Research & Development, LLC $1,950.40 12/01/2022 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 885224571
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $55.00 11/25/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937178907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $295.00 11/25/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937178911
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $832.20 11/25/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937178913
Principal investigator 1 Janssen Research & Development, LLC $6,850.00 11/22/2022 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
Phase 3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885224565
Principal investigator 1 Janssen Research & Development, LLC $459.00 11/22/2022 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
Phase 3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885224567
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 11/16/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937178459
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 11/16/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937178461
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 11/16/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937178463
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 11/16/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937178465
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $230.50 11/16/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937178467
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $36.00 11/15/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937178171
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $375.60 11/15/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937178173
Principal investigator 1 Janssen Research & Development, LLC $1,092.40 11/04/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885260171
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,924.00 10/27/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937177127
Principal investigator 1 Janssen Research & Development, LLC $1,482.40 10/17/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885260169
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 10/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937175587
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 10/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937175589
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 10/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937175591
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $276.60 10/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937175593
Principal investigator 1 ABBVIE INC. $1,440.80 10/06/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890369281
Principal investigator 1 ABBVIE INC. $80.50 09/22/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890365901
Principal investigator 1 ABBVIE INC. $199.56 09/22/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890365905
Principal investigator 1 ABBVIE INC. $250.00 09/22/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890365907
Principal investigator 1 ABBVIE INC. $39.56 09/22/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890365909
Principal investigator 1 ABBVIE INC. $232.21 09/22/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890365955
Principal investigator 1 ABBVIE INC. $40.25 09/21/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890365957
Principal investigator 1 ABBVIE INC. $8,555.20 09/08/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890365911
Principal investigator 1 Janssen Research & Development, LLC $4,131.60 09/05/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885260167
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $66.30 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173297
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173299
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173301
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173303
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173305
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173307
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173309
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173311
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173313
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173315
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173317
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173319
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173321
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.70 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173323
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173325
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173327
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173329
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173331
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937173333
Principal investigator 1 ABBVIE INC. $316.40 08/11/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890365785
Principal investigator 1 ABBVIE INC. $2,931.60 07/12/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890365465
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $919.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171257
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,007.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171259
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $869.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171261
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $869.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171263
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $869.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171265
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171267
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171269
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171271
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171273
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171275
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171277
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171279
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171281
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171283
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171285
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171287
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171289
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171291
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171293
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171295
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171297
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171299
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171301
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171303
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171305
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171307
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171309
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171311
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171313
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171315
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171317
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171319
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171321
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171323
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171325
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171327
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171329
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171331
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171333
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171335
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171337
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171339
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171341
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171343
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171345
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171347
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171349
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171351
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171353
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171355
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171357
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171359
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171361
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171363
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171365
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171367
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171369
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171371
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171373
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171375
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171377
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171379
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171381
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171383
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171385
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171387
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171389
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171391
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171393
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171395
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171397
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171399
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171401
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171403
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171405
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171407
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $347.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171409
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171411
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $919.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171413
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171415
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171417
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 07/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937171419
Principal investigator 1 Janssen Research & Development, LLC $1,482.40 06/30/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885260165
Principal investigator 1 Janssen Research & Development, LLC $1,092.40 06/02/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885260163
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $37.00 06/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937169409
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $28.00 06/02/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937169411
Principal investigator 1 ABBVIE INC. $8,555.20 05/12/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890363297
Principal investigator 1 Janssen Research & Development, LLC $1,482.40 05/09/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885260161
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $963.00 04/12/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937166645
Principal investigator 1 Janssen Research & Development, LLC $1,092.40 04/08/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885260159
Principal investigator 1 ABBVIE INC. $1,440.80 04/07/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890362965
Principal investigator 1 Janssen Research & Development, LLC $3,659.60 02/28/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885260155
Principal investigator 1 ABBVIE INC. $1,214.00 02/16/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 889777567
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $93.96 02/15/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937163365
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $93.96 02/15/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937163367
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,401.60 02/15/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937163369
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 02/15/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937163371
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,401.60 02/15/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937163373
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,268.04 02/15/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937163375
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,401.60 02/15/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937163377
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.20 02/15/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937163379
Principal investigator 1 Janssen Research & Development, LLC $4,725.00 02/04/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 885260157
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,392.17 01/25/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937162379
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $317.70 01/25/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937162381
Principal investigator 1 Janssen Research & Development, LLC $1,126.00 01/24/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 3b Multi Center Randomized Blinded Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 885260177
Principal investigator 1 ABBVIE INC. $1,214.00 01/12/2022 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 889773331
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $140.00 01/11/2022 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 937161641